![]() |
Name |
Mollicellin R
|
Molecular Formula | C21H18O6 | |
IUPAC Name* |
10-hydroxy-2,2,5,8-tetramethyl-7-oxochromeno[7,6-b][1,4]benzodioxepine-11-carbaldehyde
|
|
SMILES |
CC1=CC(=C(C2=C1C(=O)OC3=C(O2)C=C4C(=C3C)C=CC(O4)(C)C)C=O)O
|
|
InChI |
InChI=1S/C21H18O6/c1-10-7-14(23)13(9-22)19-17(10)20(24)26-18-11(2)12-5-6-21(3,4)27-15(12)8-16(18)25-19/h5-9,23H,1-4H3
|
|
InChIKey |
WERIJWMZARYEAA-UHFFFAOYSA-N
|
|
Synonyms |
Mollicellin R
|
|
CAS | NA | |
PubChem CID | 146684103 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 366.4 | ALogp: | 4.3 |
HBD: | 1 | HBA: | 6 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 82.1 | Aromatic Rings: | 4 |
Heavy Atoms: | 27 | QED Weighted: | 0.44 |
Caco-2 Permeability: | -4.935 | MDCK Permeability: | 0.00002330 |
Pgp-inhibitor: | 0.007 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.571 | 20% Bioavailability (F20%): | 0.216 |
30% Bioavailability (F30%): | 0.005 |
Blood-Brain-Barrier Penetration (BBB): | 0.042 | Plasma Protein Binding (PPB): | 100.74% |
Volume Distribution (VD): | 0.531 | Fu: | 0.67% |
CYP1A2-inhibitor: | 0.801 | CYP1A2-substrate: | 0.413 |
CYP2C19-inhibitor: | 0.751 | CYP2C19-substrate: | 0.245 |
CYP2C9-inhibitor: | 0.782 | CYP2C9-substrate: | 0.824 |
CYP2D6-inhibitor: | 0.125 | CYP2D6-substrate: | 0.242 |
CYP3A4-inhibitor: | 0.579 | CYP3A4-substrate: | 0.202 |
Clearance (CL): | 1.989 | Half-life (T1/2): | 0.225 |
hERG Blockers: | 0.007 | Human Hepatotoxicity (H-HT): | 0.043 |
Drug-inuced Liver Injury (DILI): | 0.236 | AMES Toxicity: | 0.226 |
Rat Oral Acute Toxicity: | 0.995 | Maximum Recommended Daily Dose: | 0.913 |
Skin Sensitization: | 0.833 | Carcinogencity: | 0.867 |
Eye Corrosion: | 0.006 | Eye Irritation: | 0.916 |
Respiratory Toxicity: | 0.889 |